Bladder Cancer

However, mesenchymal-like bladder cancer cells exhibited heightened sensitivity to the ferroptosis inducer Erastin, showing more pronounced suppression of proliferation, elevated ROS, higher LPO and MDA levels, and reduced GSH, confirming their enhanced susceptibility to ferroptosis...In vivo experiments further demonstrated that targeting the Smad3/CISD2 axis significantly suppressed xenograft tumor growth and activated ferroptosis. In conclusion, this study elucidates a novel mechanism by which the Smad3/CISD2 axis dynamically regulates ferroptosis through redox homeostasis reprogramming during EMT, providing a potential therapeutic strategy for targeting the progression of MIBC.

Our findings identify AHCY as a prognostic biomarker and immunometabolic regulator in BLCA, linking methionine metabolism to tumor progression, immune suppression, and drug resistance. AHCY holds promise as a therapeutic target and companion biomarker for precision oncology.

P1/2, N=292, Active, not recruiting, ImCheck Therapeutics | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Oct 2026

P=N/A, N=54, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Dec 2025 --> Dec 2026

For example, genotypes at variants in the PSCA locus were perfectly predicted by urine PSCA levels and associated with PSCA expression and diseases of PSCA-expressing tissues, including bladder cancer and urinary tract infections, demonstrating potential clinical utility of urine protein levels. These findings are accessible through a convenient web application, and establish a comprehensive genetic framework for kidney protein handling to facilitate clinical and experimental investigations.

P2, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

P=N/A, N=150, Not yet recruiting, General Hospital Sveti Duh

P3, N=112, Recruiting, Fidia Farmaceutici s.p.a. | Trial primary completion date: Nov 2025 --> Mar 2026

P2, N=16, Recruiting, Lepu Biopharma Co., Ltd.

P2, N=27, Not yet recruiting, Mayo Clinic

Furthermore, high DHRS2 predicts better survival specifically in male patients, indicating sex-specific androgen involvement. Overall, these findings elucidate the epigenetic mechanism underlying the cisplatin-sensitizing effect of Entinostat, and identifies the DHRS2-AKR1C3-androgen axis as a potential target, particularly for male patients.

Limitations include elements of study design, study populations, and confounders. There is evidence to suggest possible increased cancer risks for frequent, long-term hair dye use in specific populations.